Denali Therapeutics Quarterly Balance Sheets Chart
Quarterly
|
Annual
Denali Therapeutics Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | |||||||||||||||||||||||||||||||
| current assets: | |||||||||||||||||||||||||||||||
| cash and cash equivalents | 141,207,000 | 56,947,000 | 174,960,000 | 90,636,000 | 74,679,000 | 60,574,000 | 127,106,000 | 148,011,000 | 131,973,000 | 68,131,000 | 218,044,000 | 118,615,000 | 155,088,000 | 104,953,000 | 293,477,000 | 394,553,000 | 485,680,000 | 435,321,000 | 507,144,000 | 351,047,000 | 137,184,000 | 207,537,000 | 79,449,000 | 82,673,000 | 62,936,000 | 39,661,000 | 77,123,000 | 43,651,000 | 33,088,000 | 44,001,000 | |
| short-term marketable securities | 757,745,000 | 760,979,000 | 657,371,000 | 745,923,000 | 821,365,000 | 876,295,000 | 907,405,000 | 961,245,000 | 1,059,014,000 | 1,220,322,000 | 1,118,171,000 | 987,440,000 | 913,580,000 | 852,569,000 | 571,930,000 | 644,622,000 | 823,251,000 | 977,827,000 | 962,553,000 | 610,154,000 | 412,397,000 | 379,713,000 | 335,907,000 | 396,717,000 | 415,667,000 | 445,820,000 | 387,174,000 | 331,307,000 | 339,503,000 | 329,401,000 | |
| prepaid expenses and other current assets | 35,754,000 | 60,712,000 | 32,105,000 | 32,280,000 | 32,339,000 | 36,706,000 | 29,626,000 | 33,628,000 | 33,075,000 | 36,709,000 | 36,104,000 | 32,471,000 | 45,575,000 | 30,914,000 | 30,601,000 | 15,140,000 | 16,029,000 | 15,963,000 | 20,284,000 | 9,665,000 | 9,828,000 | 17,535,000 | 14,675,000 | 14,987,000 | 17,378,000 | 14,052,000 | 16,539,000 | 8,445,000 | 4,827,000 | 4,020,000 | |
| total current assets | 934,706,000 | 878,638,000 | 864,436,000 | 868,839,000 | 928,383,000 | 973,575,000 | 1,064,137,000 | 1,142,884,000 | 1,224,062,000 | 1,325,162,000 | 1,372,319,000 | 1,138,526,000 | 1,114,600,000 | 988,436,000 | 897,234,000 | 1,055,509,000 | 1,341,745,000 | 1,431,622,000 | 1,495,655,000 | 970,866,000 | 559,409,000 | 604,785,000 | 430,031,000 | 494,377,000 | 495,981,000 | 499,533,000 | 480,836,000 | 383,403,000 | 377,418,000 | 377,422,000 | |
| long-term marketable securities | 78,463,000 | 235,844,000 | 359,373,000 | 445,463,000 | 450,994,000 | 490,723,000 | 7,905,000 | 94,220,000 | 250,268,000 | 425,449,000 | 319,472,000 | 92,522,000 | 38,885,000 | 32,699,000 | 20,341,000 | 7,229,000 | 9,684,000 | 39,886,000 | 23,534,000 | 55,832,000 | 97,554,000 | 147,881,000 | 142,173,000 | 178,703,000 | 219,406,000 | ||||||
| property and equipment | 58,717,000 | 57,765,000 | 55,236,000 | 50,822,000 | 48,077,000 | 46,863,000 | 45,589,000 | 48,101,000 | 39,821,000 | 42,117,000 | 44,087,000 | 41,692,000 | 38,703,000 | 37,679,000 | 38,865,000 | 40,012,000 | 40,350,000 | 41,376,000 | 40,846,000 | 42,265,000 | 43,622,000 | 45,452,000 | 46,732,000 | 47,481,000 | 47,195,000 | 36,955,000 | 25,162,000 | 16,245,000 | 13,323,000 | 14,860,000 | |
| finance lease right-of-use asset | 50,363,000 | 50,199,000 | 47,533,000 | 38,685,000 | |||||||||||||||||||||||||||
| operating lease right-of-use asset | 21,022,000 | 21,963,000 | 22,861,000 | 23,717,000 | 24,533,000 | 25,309,000 | 26,048,000 | 29,755,000 | 30,263,000 | 30,743,000 | 31,196,000 | 31,622,000 | 32,236,000 | 32,618,000 | 32,976,000 | 33,312,000 | 33,626,000 | 33,923,000 | 34,344,000 | 34,647,000 | 34,407,000 | ||||||||||
| other non-current assets | 22,970,000 | 26,934,000 | 24,741,000 | 26,487,000 | 50,578,000 | 44,621,000 | 18,143,000 | 11,137,000 | 14,434,000 | 14,016,000 | 13,399,000 | 16,117,000 | 15,184,000 | 14,212,000 | 11,871,000 | 3,777,000 | 3,576,000 | 3,739,000 | 2,462,000 | 3,858,000 | 3,765,000 | 2,318,000 | 2,659,000 | 3,242,000 | 3,949,000 | 8,147,000 | 8,105,000 | 2,654,000 | 2,611,000 | 2,265,000 | |
| total assets | 1,166,241,000 | 1,271,343,000 | 1,374,180,000 | 1,454,013,000 | 1,502,565,000 | 1,581,091,000 | 1,153,917,000 | 1,236,777,000 | 1,305,734,000 | 1,409,344,000 | 1,460,242,000 | 1,227,606,000 | 1,292,462,000 | 1,320,858,000 | 1,404,162,000 | 1,449,966,000 | 1,509,815,000 | 1,547,858,000 | 1,604,280,000 | 1,070,306,000 | 647,337,000 | 695,865,000 | 553,231,000 | 602,978,000 | 637,604,000 | 676,596,000 | 661,984,000 | 544,475,000 | 572,055,000 | 613,953,000 | 486,721,000 |
| liabilities and stockholders' equity | |||||||||||||||||||||||||||||||
| current liabilities: | |||||||||||||||||||||||||||||||
| accounts payable | 10,844,000 | 8,458,000 | 11,137,000 | 9,594,000 | 13,936,000 | 11,855,000 | 9,483,000 | 1,182,000 | 8,520,000 | 2,215,000 | 2,790,000 | 7,539,000 | 7,116,000 | 3,358,000 | 4,779,000 | 4,817,000 | 4,235,000 | 1,626,000 | 1,071,000 | 2,806,000 | 1,866,000 | 2,316,000 | 2,590,000 | 2,022,000 | 3,931,000 | 3,662,000 | 1,891,000 | 3,354,000 | 9,176,000 | 1,377,000 | |
| accrued compensation | 12,068,000 | 7,655,000 | 14,874,000 | 9,555,000 | 8,053,000 | 16,344,000 | 10,256,000 | 7,365,000 | 13,253,000 | 8,315,000 | 5,844,000 | 10,534,000 | 6,295,000 | 4,963,000 | 9,010,000 | 5,531,000 | 3,910,000 | 7,528,000 | 4,092,000 | 3,213,000 | 9,952,000 | 4,847,000 | 2,751,000 | 1,994,000 | |||||||
| accrued clinical and other research and development costs | 23,379,000 | 27,908,000 | 23,923,000 | ||||||||||||||||||||||||||||
| accrued manufacturing costs | 9,028,000 | 14,579,000 | 9,568,000 | 7,111,000 | 16,720,000 | 12,421,000 | 17,263,000 | 19,959,000 | 16,732,000 | 17,929,000 | 11,366,000 | 13,142,000 | 13,052,000 | 13,342,000 | |||||||||||||||||
| operating lease liability, current | 8,871,000 | 8,585,000 | 8,036,000 | 7,771,000 | 7,512,000 | 5,871,000 | 5,659,000 | 5,252,000 | 5,055,000 | 4,876,000 | 4,508,000 | 4,330,000 | 4,121,000 | ||||||||||||||||||
| deferred research and development funding liability, current | 19,861,000 | 17,338,000 | 16,269,000 | ||||||||||||||||||||||||||||
| other accrued costs and current liabilities | 7,006,000 | 7,354,000 | 4,829,000 | 6,013,000 | 5,986,000 | 9,331,000 | 3,603,000 | 9,136,000 | 2,395,000 | 2,076,000 | 2,390,000 | 2,364,000 | 2,148,000 | ||||||||||||||||||
| total current liabilities | 91,057,000 | 91,877,000 | 102,208,000 | 87,093,000 | 74,533,000 | 82,582,000 | 77,982,000 | 71,180,000 | 69,357,000 | 391,080,000 | 363,922,000 | 360,670,000 | 348,160,000 | 341,240,000 | 378,245,000 | 54,251,000 | 51,412,000 | 54,610,000 | 71,699,000 | 105,413,000 | 58,464,000 | 47,635,000 | 45,344,000 | 46,685,000 | 46,549,000 | 43,244,000 | 32,786,000 | 31,617,000 | 31,008,000 | 17,167,000 | |
| operating lease liability, less current portion | 32,110,000 | 34,449,000 | 36,673,000 | 38,850,000 | 40,981,000 | 43,034,000 | 44,981,000 | 55,525,000 | 57,086,000 | 58,554,000 | 59,990,000 | 61,396,000 | 62,916,000 | 64,175,000 | 65,407,000 | 66,612,000 | 67,793,000 | 68,865,000 | 69,915,000 | 70,911,000 | 71,412,000 | ||||||||||
| finance lease liability, less current portion | 5,577,000 | 5,598,000 | 5,615,000 | 5,631,000 | |||||||||||||||||||||||||||
| deferred research funding and development liability, less current portion | 10,444,000 | 16,733,000 | 3,944,000 | ||||||||||||||||||||||||||||
| total liabilities | 139,188,000 | 148,657,000 | 144,496,000 | 135,518,000 | 115,514,000 | 125,616,000 | 122,963,000 | 118,446,000 | 118,909,000 | 442,638,000 | 417,812,000 | 416,303,000 | 408,014,000 | 402,931,000 | 441,871,000 | 437,689,000 | 437,110,000 | 442,505,000 | 453,749,000 | 187,756,000 | 145,170,000 | 150,554,000 | 158,341,000 | 164,781,000 | 162,431,000 | 159,948,000 | 115,139,000 | 83,296,000 | 81,783,000 | 74,925,000 | 20,925,000 |
| commitments and contingencies | |||||||||||||||||||||||||||||||
| stockholders' equity: | |||||||||||||||||||||||||||||||
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of june 30, 2025 and december 31, 2024; 0 shares issued and outstanding as of june 30, 2025 and december 31, 2024 | |||||||||||||||||||||||||||||||
| common stock | 1,783,000 | 1,778,000 | 1,768,000 | 1,764,000 | 1,757,000 | 1,751,000 | 1,711,000 | 1,707,000 | 1,700,000 | 1,694,000 | 1,686,000 | 1,564,000 | 1,558,000 | 1,554,000 | 1,548,000 | 1,545,000 | 1,541,000 | 1,537,000 | 1,531,000 | 1,524,000 | 1,385,000 | 1,382,000 | 1,288,000 | 1,286,000 | 1,283,000 | 1,279,000 | 1,273,000 | 1,266,000 | 1,259,000 | 1,252,000 | |
| additional paid-in capital | 2,820,404,000 | 2,790,825,000 | 2,764,880,000 | 2,735,433,000 | 2,704,992,000 | 2,673,033,000 | 2,144,811,000 | 2,114,013,000 | 2,083,951,000 | 2,048,297,000 | 2,018,617,000 | 1,693,901,000 | 1,664,174,000 | 1,635,840,000 | 1,608,238,000 | 1,580,988,000 | 1,556,679,000 | 1,528,504,000 | 1,503,660,000 | 1,480,315,000 | 1,041,303,000 | 1,025,408,000 | 818,803,000 | 807,875,000 | 798,277,000 | 781,966,000 | 774,158,000 | 766,799,000 | 760,605,000 | 754,438,000 | |
| accumulated other comprehensive income | 939,000 | 2,037,000 | 2,020,000 | 5,529,000 | -2,659,000 | -1,296,000 | 643,000 | -245,000 | 11,000 | 551,000 | 835,000 | 350,000 | 562,000 | 879,000 | 332,000 | ||||||||||||||||
| accumulated deficit | -1,796,073,000 | -1,671,954,000 | -1,538,984,000 | -1,424,231,000 | -1,317,039,000 | -1,218,013,000 | -1,116,211,000 | -996,738,000 | -897,385,000 | -1,080,768,000 | -970,987,000 | -872,309,000 | -769,010,000 | -710,216,000 | -644,996,000 | -569,735,000 | -485,147,000 | -424,456,000 | -354,415,000 | -599,300,000 | -541,072,000 | -482,314,000 | -425,551,000 | -371,526,000 | -325,266,000 | -266,929,000 | -227,937,000 | -305,470,000 | -270,099,000 | -215,375,000 | -191,697,000 |
| total stockholders' equity | 1,027,053,000 | 1,122,686,000 | 1,318,495,000 | 1,387,051,000 | 1,455,475,000 | 1,118,331,000 | 1,186,825,000 | 966,706,000 | 811,303,000 | 884,448,000 | 917,927,000 | 1,012,277,000 | 1,072,705,000 | 1,105,353,000 | 882,550,000 | 502,167,000 | 545,311,000 | 438,197,000 | 475,173,000 | 516,648,000 | 461,179,000 | 490,272,000 | |||||||||
| total liabilities and stockholders’ equity | 1,166,241,000 | 1,271,343,000 | 1,374,180,000 | 1,454,013,000 | 1,502,565,000 | 1,581,091,000 | 1,153,917,000 | 1,236,777,000 | 1,305,734,000 | 1,409,344,000 | 1,460,242,000 | 1,227,606,000 | 1,292,462,000 | 1,320,858,000 | 1,404,162,000 | 1,449,966,000 | 1,509,815,000 | 1,547,858,000 | 1,604,280,000 | 1,070,306,000 | 647,337,000 | 695,865,000 | 553,231,000 | 602,978,000 | 637,604,000 | 676,596,000 | 661,984,000 | 544,475,000 | 572,055,000 | 613,953,000 | |
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of march 31, 2025 and december 31, 2024; 0 shares issued and outstanding as of march 31, 2025 and december 31, 2024 | |||||||||||||||||||||||||||||||
| liabilities and stockholders’ equity | |||||||||||||||||||||||||||||||
| accrued expenses and other current liabilities | 91,071,000 | 68,499,000 | 66,691,000 | 53,165,000 | 47,145,000 | 24,015,000 | |||||||||||||||||||||||||
| stockholders’ equity: | |||||||||||||||||||||||||||||||
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of december 31, 2024 and december 31, 2023; 0 shares issued and outstanding as of december 31, 2024 and december 31, 2023 | |||||||||||||||||||||||||||||||
| total stockholders’ equity | 1,229,684,000 | 1,030,954,000 | 1,042,430,000 | 962,291,000 | 1,150,531,000 | 394,890,000 | 546,845,000 | 539,028,000 | 465,796,000 | ||||||||||||||||||||||
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of september 30, 2024 and december 31, 2023; 0 shares issued and outstanding as of september 30, 2024 and december 31, 2023 | |||||||||||||||||||||||||||||||
| accrued clinical and other research & development costs | 19,915,000 | 19,956,000 | 14,534,000 | 15,120,000 | 47,571,000 | 21,701,000 | 16,429,000 | 19,283,000 | 13,380,000 | 11,434,000 | |||||||||||||||||||||
| deferred research funding liability | 10,232,000 | ||||||||||||||||||||||||||||||
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of june 30, 2024 and december 31, 2023; 0 shares issued and outstanding as of june 30, 2024 and december 31, 2023 | |||||||||||||||||||||||||||||||
| deferred research funding liability, current | 12,500,000 | ||||||||||||||||||||||||||||||
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of march 31, 2024 and december 31, 2023; 0 shares issued and outstanding as of march 31, 2024 and december 31, 2023 | |||||||||||||||||||||||||||||||
| cost sharing payments due to related party | 10,354,000 | 6,976,000 | 8,538,000 | 4,388,000 | 1,443,000 | 2,713,000 | |||||||||||||||||||||||||
| related party contract liability, current | 290,053,000 | 290,627,000 | 292,386,000 | 3,438,000 | 3,438,000 | 3,569,000 | 3,569,000 | ||||||||||||||||||||||||
| related party contract liability, less current portion | 479,000 | 828,000 | 1,295,000 | 291,434,000 | 292,293,000 | 292,956,000 | 293,849,000 | ||||||||||||||||||||||||
| other non-current liabilities | 379,000 | 379,000 | 379,000 | 379,000 | 379,000 | 379,000 | 379,000 | 379,000 | 701,000 | 701,000 | 701,000 | 701,000 | 379,000 | 379,000 | 379,000 | 379,000 | 386,000 | 408,000 | 440,000 | 471,000 | 124,000 | 156,000 | 188,000 | ||||||||
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of december 31, 2023 and december 31, 2022; 0 shares issued and outstanding as of december 31, 2023 and december 31, 2022 | |||||||||||||||||||||||||||||||
| operating lease right-of-use assets | 26,750,000 | 27,417,000 | 28,049,000 | 30,437,000 | 31,271,000 | ||||||||||||||||||||||||||
| operating lease liabilities, current | 7,014,000 | 6,774,000 | 6,539,000 | 7,068,000 | |||||||||||||||||||||||||||
| related-party contract liability, current | 845,000 | 289,757,000 | 290,516,000 | 290,424,000 | |||||||||||||||||||||||||||
| related-party contract liability, less current portion | 422,000 | 633,000 | 276,000 | 552,000 | |||||||||||||||||||||||||||
| operating lease liabilities, less current portion | 46,887,000 | 48,751,000 | 50,546,000 | 53,032,000 | 54,978,000 | ||||||||||||||||||||||||||
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of september 30, 2023 and december 31, 2022; 0 shares issued and outstanding as of september 30, 2023 and december 31, 2022 | |||||||||||||||||||||||||||||||
| accumulated other comprehensive loss | -651,000 | -1,441,000 | -2,517,000 | -6,886,000 | -11,853,000 | -12,274,000 | -9,251,000 | -2,499,000 | -521,000 | -368,000 | -232,000 | -649,000 | -1,416,000 | -1,493,000 | -1,287,000 | ||||||||||||||||
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of june 30, 2023 and december 31, 2022; 0 shares issued and outstanding as of june 30, 2023 and december 31, 2022 | |||||||||||||||||||||||||||||||
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of march 31, 2023 and december 31, 2022; 0 shares issued and outstanding as of march 31, 2023 and december 31, 2022 | |||||||||||||||||||||||||||||||
| cost sharing reimbursements due from related party | 357,000 | 1,226,000 | 1,194,000 | 1,567,000 | 2,511,000 | 5,674,000 | |||||||||||||||||||||||||
| contract liabilities, current | 23,000 | 27,915,000 | 1,324,000 | 5,755,000 | 12,886,000 | 19,914,000 | |||||||||||||||||||||||||
| contract liabilities, less current portion | 3,398,000 | 3,398,000 | 3,398,000 | 31,313,000 | 31,308,000 | 31,322,000 | 23,325,000 | 16,557,000 | 19,715,000 | 34,747,000 | 43,753,000 | 47,795,000 | 44,563,000 | 44,852,000 | |||||||||||||||||
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of december 31, 2022 and december 31, 2021; 0 shares issued and outstanding as of december 31, 2022 and december 31, 2021 | |||||||||||||||||||||||||||||||
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of september 30, 2022 and december 31, 2021; 0 shares issued and outstanding as of september 30, 2022 and december 31, 2021 | |||||||||||||||||||||||||||||||
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of june 30, 2022 and december 31, 2021; 0 shares issued and outstanding as of june 30, 2022 and december 31, 2021 | |||||||||||||||||||||||||||||||
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of march 31, 2022 and december 31, 2021; 0 shares issued and outstanding as of march 31, 2022 and december 31, 2021 | |||||||||||||||||||||||||||||||
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of december 31, 2021 and december 31, 2020; 0 shares issued and outstanding as of december 31, 2021 and december 31, 2020 | |||||||||||||||||||||||||||||||
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of september 30, 2021 and december 31, 2020; 0 shares issued and outstanding as of september 30, 2021 and december 31, 2020 | |||||||||||||||||||||||||||||||
| accounts receivable | 15,218,000 | ||||||||||||||||||||||||||||||
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of june 30, 2021 and december 31, 2020; 0 shares issued and outstanding as of june 30, 2021 and december 31, 2020 | |||||||||||||||||||||||||||||||
| accrued clinical costs | 5,049,000 | 4,689,000 | 4,179,000 | 5,349,000 | |||||||||||||||||||||||||||
| other accruals and other current liabilities | 8,299,000 | 11,531,000 | 8,424,000 | 7,265,000 | |||||||||||||||||||||||||||
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of march 31, 2021 and december 31, 2020; 0 shares issued and outstanding as of march 31, 2021 and december 31, 2020 | |||||||||||||||||||||||||||||||
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of december 31, 2020 and december 31, 2019; 0 shares issued and outstanding as of december 31, 2020 and december 31, 2019 | |||||||||||||||||||||||||||||||
| related party contract liability | 44,854,000 | ||||||||||||||||||||||||||||||
| other contract liabilities | 28,015,000 | ||||||||||||||||||||||||||||||
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of september 30, 2020 and december 31, 2019; 0 shares issued and outstanding as of september 30, 2020 and december 31, 2019 | |||||||||||||||||||||||||||||||
| contract liabilities | 34,134,000 | 24,674,000 | 18,739,000 | 18,185,000 | 22,598,000 | 23,148,000 | |||||||||||||||||||||||||
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of june 30, 2020 and december 31, 2019; 0 shares issued and outstanding as of june 30, 2020 and december 31, 2019 | |||||||||||||||||||||||||||||||
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of march 31, 2020 and december 31, 2019; 0 shares issued and outstanding as of march 31, 2020 and december 31, 2019 | |||||||||||||||||||||||||||||||
| deferred rent, less current portion | 24,532,000 | 7,103,000 | 1,029,000 | 6,051,000 | |||||||||||||||||||||||||||
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of december 31, 2019 and december 31, 2018; 0 shares issued and outstanding as of december 31, 2019 and december 31, 2018 | |||||||||||||||||||||||||||||||
| accrued liabilities | 15,467,000 | 13,793,000 | 12,114,000 | 8,520,000 | 7,393,000 | 5,537,000 | 4,425,000 | ||||||||||||||||||||||||
| other current liabilities | 3,483,000 | 2,135,000 | 1,107,000 | 380,000 | 138,000 | 47,000 | 63,000 | ||||||||||||||||||||||||
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of september 30, 2019 and december 31, 2018; 0 shares issued and outstanding as of september 30, 2019 and december 31, 2018 | |||||||||||||||||||||||||||||||
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of june 30, 2019 and december 31, 2018; 0 shares issued and outstanding as of june 30, 2019 and december 31, 2018 | |||||||||||||||||||||||||||||||
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of march 31, 2019 and december 31, 2018; 0 shares issued and outstanding as of march 31, 2019 and december 31, 2018 | |||||||||||||||||||||||||||||||
| contract liability | 11,427,000 | 12,658,000 | 8,715,000 | 8,434,000 | |||||||||||||||||||||||||||
| deferred rent | 616,000 | 3,227,000 | 4,782,000 | 874,000 | |||||||||||||||||||||||||||
| contract liability, less current portion | 57,350,000 | 44,452,000 | 49,590,000 | 51,519,000 | |||||||||||||||||||||||||||
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of december 31, 2018 and december 31, 2017; 0 shares issued and outstanding as of december 31, 2018 and december 31, 2017 | |||||||||||||||||||||||||||||||
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of september 30, 2018 and december 31, 2017; 0 shares issued and outstanding as of september 30, 2018 and december 31, 2017 | |||||||||||||||||||||||||||||||
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of june 30, 2018 and december 31, 2017; 0 shares issued and outstanding as of june 30, 2018 and december 31, 2017 | |||||||||||||||||||||||||||||||
| convertible preferred stock, 0.01 par value; 40,000,000 shares authorized as of march 31, 2018 and december 31, 2017; 0 shares issued and outstanding as of march 31, 2018 and december 31, 2017 | |||||||||||||||||||||||||||||||
| consolidated balance sheets data: | |||||||||||||||||||||||||||||||
| cash, cash equivalents and marketable securities | 466,976,000 | ||||||||||||||||||||||||||||||
| working capital | 395,443,000 | ||||||||||||||||||||||||||||||
| convertible preferred stock |
We provide you with 20 years of balance sheets for Denali Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Denali Therapeutics. Explore the full financial landscape of Denali Therapeutics stock with our expertly curated balance sheets.
The information provided in this report about Denali Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.